Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics, Inc.’s Chief Medical Officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 45,000 shares at $2.48 per share, converting them into 45,000 shares of common stock.
She then sold 45,000 common shares at a weighted average price of $26.1747, with trade prices ranging from $25.76 to $26.695, under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of common stock and 221,268 option shares, all of which were fully vested and exercisable as of the transaction date.
Enliven Therapeutics Inc. reported proposed resale transactions of common stock via Jefferies LLC for 75,000 shares with an aggregate value of $1,959,750 as of 02/18/2026. The filing also lists multiple executed sales by Joseph Lyssikatos between 12/19/2025 and 02/06/2026, totaling reported proceeds of $4,234,611.77 across five transactions.
Kunkel Lori Anne reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Lori Anne Kunkel received a new stock option grant covering 17,126 shares of the company’s stock. The option was awarded as a derivative security and is held directly. According to the terms, all shares vest in a single installment.
The option will fully vest on the earlier of the first anniversary of Enliven’s 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, provided Kunkel continues serving as a non-employee director through that vesting date.
Enliven Therapeutics director Richard A. Heyman received a grant of stock options for 19,234 shares of Enliven common stock. The options have an exercise price of $0.00 per share. They vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director.
Gupta Rishi reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Rishi Gupta reported stock option grants. He was awarded options covering 33,989 shares and 1,580 shares. For the larger grant, 1/36 of the shares vest monthly starting on February 2, 2026, while the smaller grant fully vests around the company’s 2027 annual stockholder meeting.
Garland J. Scott reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Garland J. Scott reported receiving a grant of stock options covering 1,427 shares of common stock. The award was made at a reported price of $0.00 per share.
All 1,427 options will vest in full on the earlier of the first anniversary of Enliven's 2026 annual stockholder meeting or the date of its 2027 annual meeting, as long as Scott continues serving as a non-employee director through that vesting date.
Enliven Therapeutics, Inc. reported that director Mika K. Derynck acquired a stock option covering 17,126 shares of common stock. This was a granted award, bringing the director’s directly held stock options to 17,126 shares following the transaction.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as the director continues serving as a non-employee director through the applicable vesting date.
Enliven Therapeutics director Jake Bauer reported a new equity award. He received a grant of stock options covering 17,126 shares at an exercise price of $0.00 per share. According to the terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director through that vesting date.
Ballal Rahul D. reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics, Inc. reported that director Rahul D. Ballal received a grant of 17,126 stock options. The transaction is coded as a grant or award and recorded with a transaction price of $0.00 per option.
According to the vesting terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as Ballal continues serving as a non-employee director through that vesting date.
Enliven Therapeutics reported new equity awards for Chief Operating Officer Anish Patel. On February 12, 2026, he received a stock option covering 120,000 shares of common stock at an exercise price of $0.00 per share, vesting 25% on February 12, 2027 and the remainder in equal monthly installments thereafter. He also acquired 20,000 restricted stock units, each representing one share of common stock, with 25% vesting on March 1, 2027 and the balance vesting in equal installments each June 1, September 1, December 1, and March 1 thereafter, while he continues as a service provider. In addition, an indirect holding of 215,011 common shares is reported as held by The Patel / Dong Family Trust, for which he serves as trustee.